🇺🇸 FDA

Company profile · Sponsor

Ology

Ology Bioservices Ireland LTD

EA874D0 · EMA pharma GB
Pipeline
24
Drugs
0
Patents
0

Quick answer

Ology (EA874D0) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EA874D0
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (24)

Search pipeline →

  1. AC-203, Vehicle ointment (Placebo of AC-203 Diacerein 1% Ointment, EU)

    Ology

    Generalized Epidermolysis Bullosa Simplex (EBS)

    phase 3 small molecule active

    1 trial

  2. IBRUTINIB, PIRTOBRUTINIB, PIRTOBRUTINIB

    Ology

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  3. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ology

    Small-cell lung cancer, extensive stage

    phase 3 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 734506

    Ology

    Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.

    phase 3 small molecule active

    1 trial

  5. METHOTREXATE, IFOSFAMIDE, VINCRISTINE, CYCLOPHOSPHAMIDE, RITUXIMAB, ETOPOSIDE, CYTARABINE, PREDNISOLONE, DOXORUBICIN

    Ology

    Burkitt lymphoma

    phase 3 small molecule active

    1 trial

  6. Natriumklorid B. Braun 9 mg/ml infusjonsvæske, oppløsning, BOTOX 50 Allergan-enheter Pulver til injeksjonsvæske, oppløsning

    Ology

    Chronic cluster headache

    phase 3 small molecule active

    1 trial

  7. PIRTOBRUTINIB, IBRUTINIB, PIRTOBRUTINIB, IBRUTINIB

    Ology

    Mantle cell lymphoma

    phase 3 small molecule active

    1 trial

  8. PIRTOBRUTINIB, IDELALISIB, RITUXIMAB, BENDAMUSTINE HYDROCHLORIDE, PIRTOBRUTINIB, IDELALISIB

    Ology

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  9. PIRTOBRUTINIB, RITUXIMAB, PIRTOBRUTINIB, BENDAMUSTINE

    Ology

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  10. Prolia 60 mg solution for injection in pre-filled syringe, LY06006

    Ology

    Postmenopausal osteoporosis

    phase 3 small molecule active

    1 trial

  11. TOPOTECAN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NEMVALEUKIN ALFA, GEMCITABINE HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

    Ology

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  12. VENETOCLAX, RITUXIMAB, PIRTOBRUTINIB, PIRTOBRUTINIB, VENETOCLAX

    Ology

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

    phase 3 small molecule active

    1 trial

  13. evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)

    Ology

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

  14. 177Lu PSMA I&T solution for injection

    Ology

    Recurrent grade 3 and grade 4 glioma

    phase 2 small molecule active

    1 trial

  15. A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

    Ology

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

    phase 2 other active

    1 trial

  16. A phase II trial aiming to investigate the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia previously treated with a thrombopoietin receptor agonist and/or rituximab after corticosteroid first-line therapy - BONSAI

    Ology

    Primary Immune Thrombocytopenia

    phase 2 other active

    1 trial

  17. CYCLOPHOSPHAMIDE MONOHYDRATE, BORTEZOMIB, ISATUXIMAB, LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE

    Ology

    Newly diagnosed patients with multiple myeloma and severe renal impairment

    phase 2 small molecule active

    1 trial

  18. DEXAMETHASONE, DEXAMETHASONE, LENALIDOMIDE, DARATUMUMAB

    Ology

    newly diagnosed multiple myeloma

    phase 2 small molecule active

    1 trial

  19. DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE

    Ology

    Newly diagnosed multiple myeloma

    phase 2 small molecule active

    1 trial

  20. DT-DEC01

    Ology

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  21. Diamyd

    Ology

    Latent Autoimmune Diabetes in Adults (LADA)

    phase 2 small molecule active

    1 trial

  22. Etrinabdione oral solution

    Ology

    Peripheral Arterial Disease

    phase 2 small molecule active

    1 trial

  23. Fluorouracil Injection 25 mg/ml, solution for injection, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, Irinotecan Hydrochloride 20 mg/mL concentrate for solution for infusion

    Ology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  24. GEMCITABINE

    Ology

    Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Ology?

Ology (EA874D0) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Ology sponsor?

We track 24 ClinicalTrials.gov-linked programs for Ology, including AC-203, Vehicle ointment (Placebo of AC-203 Diacerein 1% Ointment, EU) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Ology company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.